Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVXL NASDAQ:OCS NASDAQ:RZLT NYSE:VOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVXLAnavex Life Sciences$8.50+0.7%$10.08$5.03▼$14.44$724.94M0.831.04 million shs689,918 shsOCSOculis$17.50-1.2%$17.52$11.91▼$23.08$773.70M0.2620,285 shs36,476 shsRZLTRezolute$8.77-0.5%$6.88$2.21▼$9.02$800.05M0.031.23 million shs1.28 million shsVORVor Biopharma$33.81-2.5%$39.27$2.62▼$65.80$214.15M2.05381,746 shs434,310 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVXLAnavex Life Sciences+0.71%-1.96%-10.81%-10.34%+55.96%OCSOculis-1.24%+0.57%-0.17%-9.56%+44.99%RZLTRezolute-0.45%+6.95%+21.81%+101.61%+77.17%VORVor Biopharma-2.54%+11.22%-18.73%+59.48%+122.43%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVXLAnavex Life Sciences$8.50+0.7%$10.08$5.03▼$14.44$724.94M0.831.04 million shs689,918 shsOCSOculis$17.50-1.2%$17.52$11.91▼$23.08$773.70M0.2620,285 shs36,476 shsRZLTRezolute$8.77-0.5%$6.88$2.21▼$9.02$800.05M0.031.23 million shs1.28 million shsVORVor Biopharma$33.81-2.5%$39.27$2.62▼$65.80$214.15M2.05381,746 shs434,310 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVXLAnavex Life Sciences+0.71%-1.96%-10.81%-10.34%+55.96%OCSOculis-1.24%+0.57%-0.17%-9.56%+44.99%RZLTRezolute-0.45%+6.95%+21.81%+101.61%+77.17%VORVor Biopharma-2.54%+11.22%-18.73%+59.48%+122.43%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVXLAnavex Life Sciences 3.00Buy$44.00417.65% UpsideOCSOculis 3.00Buy$35.75104.29% UpsideRZLTRezolute 3.14Buy$14.5065.34% UpsideVORVor Biopharma 2.56Moderate Buy$113.83236.69% UpsideCurrent Analyst Ratings BreakdownLatest VOR, OCS, AVXL, and RZLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/24/2025VORVor BiopharmaStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$55.009/22/2025RZLTRezoluteGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.009/18/2025RZLTRezoluteMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $20.009/18/2025RZLTRezoluteWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$12.009/18/2025RZLTRezoluteBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$17.009/10/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$42.009/10/2025AVXLAnavex Life SciencesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$46.009/3/2025RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.008/27/2025AVXLAnavex Life SciencesD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$46.008/27/2025OCSOculisNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$36.008/22/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$42.00(Data available from 9/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVXLAnavex Life SciencesN/AN/AN/AN/A$1.42 per shareN/AOCSOculis$780K979.55N/AN/A$1.91 per share9.16RZLTRezoluteN/AN/AN/AN/A$1.86 per shareN/AVORVor BiopharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVXLAnavex Life Sciences-$43M-$0.57N/AN/AN/AN/A-45.67%-40.21%N/AOCSOculis-$97.43M-$2.67N/AN/AN/A-13,958.12%-90.31%-67.85%11/6/2025 (Estimated)RZLTRezolute-$74.41M-$0.97N/AN/AN/AN/A-65.03%-58.86%11/6/2025 (Estimated)VORVor BiopharmaN/A-$273.20N/AN/AN/AN/AN/AN/AN/ALatest VOR, OCS, AVXL, and RZLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/17/2025Q4 2025RZLTRezolute-$0.23-$0.26-$0.03-$0.26N/AN/A8/21/2025Q2 2025OCSOculis-$0.53-$0.59-$0.06-$0.59$0.14 million$0.25 million8/12/2025Q3 2025AVXLAnavex Life Sciences-$0.13-$0.16-$0.03-$0.16N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVXLAnavex Life SciencesN/AN/AN/AN/AN/AOCSOculisN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/AVORVor BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVXLAnavex Life SciencesN/A8.938.93OCSOculis0.014.554.55RZLTRezoluteN/A14.3714.37VORVor BiopharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVXLAnavex Life Sciences31.55%OCSOculis22.30%RZLTRezolute82.97%VORVor Biopharma97.29%Insider OwnershipCompanyInsider OwnershipAVXLAnavex Life Sciences11.40%OCSOculisN/ARZLTRezolute18.39%VORVor Biopharma0.45%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVXLAnavex Life Sciences4085.89 million76.10 millionOptionableOCSOculis243.66 millionN/ANot OptionableRZLTRezolute4090.81 million74.11 millionOptionableVORVor Biopharma1406.33 million65.45 millionNot OptionableVOR, OCS, AVXL, and RZLT HeadlinesRecent News About These CompaniesVor Biopharma (NYSE:VOR) Raised to "Buy" at Stifel Nicolaus2 hours ago | americanbankingnews.comVor Biopharma (NYSE:VOR) and Prime Medicine (NASDAQ:PRME) Critical Survey2 hours ago | americanbankingnews.comVor Biopharma: Transformed Company Is A High Risk Buy On Autoimmune Disease PromiseSeptember 25 at 12:00 PM | seekingalpha.comVor Biopharma upgraded to Buy at Stifel on telitacicept prospectsSeptember 24 at 12:59 PM | msn.comStifel Nicolaus Upgrades Vor Biopharma (NYSE:VOR) to BuySeptember 24 at 8:14 AM | marketbeat.comVor Biopharma Shares Rise After Appointment of Navid Khan as Medical Affairs ChiefSeptember 23 at 4:55 PM | marketwatch.comVor Bio Appoints Navid Z. Khan, Ph.D.September 23 at 8:00 AM | globenewswire.comComparing Vor Biopharma (NYSE:VOR) & Prime Medicine (NASDAQ:PRME)September 23 at 2:51 AM | americanbankingnews.comVor Biopharma (NYSE:VOR) Trading Down 8.6% on Insider SellingSeptember 21, 2025 | americanbankingnews.comReprogrammed Interchange Llc Sells 447,278 Shares of Vor Biopharma (NYSE:VOR) StockSeptember 20, 2025 | marketbeat.comVor Biopharma (NYSE:VOR) Stock Price Down 8.6% After Insider SellingSeptember 20, 2025 | marketbeat.comVor Biopharma (NYSE:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 447,278 SharesSeptember 19, 2025 | marketbeat.comVor Biopharma trading halted on Thursday, news pendingSeptember 19, 2025 | msn.comVor Biopharma trading halted, news pendingSeptember 19, 2025 | msn.comVor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of "Moderate Buy" by BrokeragesSeptember 18, 2025 | marketbeat.comHead to Head Survey: Prime Medicine (NASDAQ:PRME) versus Vor Biopharma (NYSE:VOR)September 18, 2025 | americanbankingnews.comResults of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual MeetingSeptember 17, 2025 | prnewswire.comVor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEMSeptember 17, 2025 | globenewswire.comReprogrammed Interchange Llc Sells 284,805 Shares of Vor Biopharma (NYSE:VOR) StockSeptember 16, 2025 | marketbeat.comVor Biopharma (NYSE:VOR) Major Shareholder Sells $525,000.00 in StockSeptember 16, 2025 | marketbeat.comVor Biopharma (NYSE:VOR) Major Shareholder Sells $656,000.00 in StockSeptember 16, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesNIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 2025The Most Upgraded Stocks in Q3: Good News for the S&P 500By Thomas Hughes | September 17, 2025Why Seagate Is Wall Street's New Favorite AI Infrastructure PlayBy Jeffrey Neal Johnson | September 18, 2025Rezolute Stock: FDA Fast Track Fuels 2025 BreakoutBy Thomas Hughes | September 17, 2025Ford Set to Outpace GM With Tariff Tailwinds and EPS MomentumBy Gabriel Osorio-Mazilli | September 24, 2025VOR, OCS, AVXL, and RZLT Company DescriptionsAnavex Life Sciences NASDAQ:AVXL$8.50 +0.06 (+0.71%) Closing price 09/25/2025 04:00 PM EasternExtended Trading$8.45 -0.05 (-0.59%) As of 09/25/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Oculis NASDAQ:OCS$17.50 -0.22 (-1.24%) Closing price 09/25/2025 04:00 PM EasternExtended Trading$17.46 -0.04 (-0.23%) As of 09/25/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.Rezolute NASDAQ:RZLT$8.77 -0.04 (-0.45%) Closing price 09/25/2025 04:00 PM EasternExtended Trading$8.77 0.00 (0.00%) As of 09/25/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.Vor Biopharma NYSE:VOR$33.81 -0.88 (-2.54%) Closing price 09/25/2025 04:00 PM EasternExtended Trading$31.90 -1.91 (-5.63%) As of 09/25/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas It's a Good Time to Build a Position in KB Home Alphabet: Time to Take Profits, Buy, or Wait for a Pullback? Cintas Stock Sends a Clear Buy Signal as Momentum Builds Thor Industries Tracking for New Highs in 2026 Micron’s Stock Price Rally Is Not Over: MU $190 Is Coming Soon NuScale Power: The SMR Stock at the Heart of the AI Energy Boom Intel + NVIDIA: The Unexpected AI Alliance Shaking Wall Street Why Traders Are Doubling Down on SoundHound Stock After Big Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
